Getting the HPV vaccine in early adolescence may lower the risk of HPV-related cancers before exposure occurs. Learn about ...
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...
As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer ... to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 ...
Excluding the impact of foreign exchange, sales increased 9%. Merck reported adjusted ... Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer ...